fbpx

London-based blood sensing startup Zedsen raises £8.6M; aims to capture £6.4T healthtech market

Zedsen

Every health app created so far relies on data gathered from outside the body, such as heart rate, temperature, and movement. But for diabetes, data is gleaned from the blood but still requires needles or patches that puncture the skin. 

However, the UK company Zedsen provides the crucial window into the body not through needles or patches but through sensors that sit on the skin’s surface. The company helps consumers understand their health based on data coming from their bloodstream. 

£8.6M funding and investors

Recently, the London-based company has secured $12 million (approx £8.6 million) at a $110 million (approx £79 million) valuation. 

The investors include Joseph R. Grano, former Chairman and CEO of UBS Financial Services Inc; Nasser Kazeminy, Investor, Founder of NJK Holding and Chairman of the Ellis Island Honor Society (EIHS); Tony Rice, Former CEO of Cable and Wireless; Bonnie Mcalveen Hunter, Chairperson of the Red Cross; and Jim Harpel, Investor at Palm Beach Capital.

As a part of the round, Dr. Caroline Hargrove, former CTO of Babylon Health has been appointed as Chief Technology Officer.

Offers precise understanding of health

Zedsen biosensors create a 3-Dimensional electrical field that measures the permittivity and conductivity of materials. When coupled with complex algorithms, they are capable of non-invasively monitoring trends within our bodies.

By analysing the combination of internal and external data, Zedsen can more precisely give users an understanding of their health so they can make small lifestyle changes that have significant long-term benefits.

According to the company, the potential use cases are wide-ranging from spotting pre-diabetes to tracking fertility

Furthermore, the data gathered leads to hyper-personalised insights about health, fitness, and diet, with support and suggestions as unique as each individual user.

“Low-cost, non-invasive technology for monitoring blood to a high standard is the holy grail that has profound, life-enhancing impact – whether you are monitoring metabolic health to improve athletic performance, or working to reverse the trend towards diabetes. I’m delighted to be working on developing such transformative products based on Zedsen’s novel non-invasive technology and being part of Zedsen’s amazing team,” said Dr. Hargrove.

“Caroline’s technical expertise will be intrinsic to the next stage of our journey, but most importantly, we are inspired and excited by her vision for hyper-personalised healthcare,” said Zedsen CEO Daniel Honeywell. “Neither of us can accept the status quo. Chronic disease accounts for 41 million avoidable deaths each year. Knowing this can be prevented through meaningful biological insights and manageable lifestyle changes will allow us to actually deliver on the promise of proactive, personalised, and preventative care.”